Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
targeted therapies
Biotech
Nuvalent trots out strong pivotal data in FDA lung cancer push
Nuvalent is eyeing an FDA rolling submission for its ROS1 inhibitor in TKI-pretreated lung cancer after releasing competitive pivotal data.
Angus Liu
Jun 24, 2025 6:30am
Tyra banks $173M to bring cancer resistance programs into clinic
Sep 15, 2021 10:20am
AstraZeneca, Thermo Fisher launch multiyear diagnostic project
Sep 1, 2021 10:45am
Nuvalent banks $166M IPO to push resistance-beating cancer drugs
Jul 29, 2021 11:20am
Erasca nabs $300M IPO to attack cancer's favorite pathway
Jul 16, 2021 10:10am
Ionis pays $45M to expand oligonucleotide delivery toolkit
Jul 13, 2021 8:20am
